Evidence map›Paper›PMID 28614829›Full record

ReviewNephron2017

AKI Adjudication: Do We Need It.

Yuenting D Kwong, Kathleen D Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nephron, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Adjudicating the Diagnosis of Immune Thrombocytopenia in a Clinical Research Study.TH open : companion journal to thrombosis and haemostasis · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Yuenting D KwongDivision of Nephrology, Department of Medicine, University of California, San Francisco, CA, USA.
Kathleen D Liu

Funding

UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI AGARWAL, ANUPAM · 2008 to 2022
$18.3M
Academic Training Program in NephrologyT32DK007219 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN · 1986 to 2022
$7.3M
Advancing acute kidney injury phenotyping using biological and clinical criteriaK24DK113381 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIU, KATHLEEN D · 2017 to 2021
$915k
NIDDK NIH HHS K24 DK113381NIDDK NIH HHS P30 DK079337NIDDK NIH HHS T32 DK007219
6 · The paper itself

Abstract

Adjudication, which comes from the Latin term "adjudicare" (to act as a judge), uses expert opinion to define and classify disease entities. The use of clinical adjudication may help to define more homogeneous disease subsets but comes at the expense of effort needed and generalizability. Here, we will describe the pros and cons of acute kidney injury (AKI) adjudication under varied circumstances. We will use heart failure as a paradigm and provide comparable examples from the current AKI literature.

Indexed as

Acute Kidney InjuryBiomarkersHeart FailureHumansBiomarkersAcute renal failureDisease categoriesHeart failure

Identifiers

PMID28614829
PMCPMC7050274

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.